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Abstract: When cellular reducing enzymes fail to shield the cell from increased amounts 
of reactive oxygen species (ROS), oxidative stress arises. The redox state is misbalanced, 
DNA and proteins are damaged and cellular transcription networks are activated. This 
condition can lead to the initiation and/or to the progression of atherosclerosis, tumors or 
pulmonary hypertension; diseases that are decisively furthered by the presence of oxidizing 
agents. Redox sensitive genes, like the zinc finger transcription factor early growth 
response 1 (Egr-1), play a pivotal role in the pathophysiology of these diseases. Apart from 
inducing apoptosis, signaling partners like the MEK/ERK pathway or the protein kinase C 
(PKC) can activate salvage programs such as cell proliferation that do not ameliorate, but 
rather worsen their outcome. Here, we review the currently available data on Egr-1 related 
signal transduction cascades in response to oxidative stress in the progression of 
epidemiologically significant diseases. Knowing the molecular pathways behind the 
pathology will greatly enhance our ability to identify possible targets for the development 
of new therapeutic strategies.  
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1. Introduction 
Redox reactions contribute to countless significant biological processes and help to maintain vital 
cellular functions. During aerobic cellular respiration, for instance, glucose is oxidized to CO2 and 
oxygen is reduced to water. This key process is elementary to gain energy in the form of adenosine 
triphosphate (ATP). Coenzymes like nicotinamide adenine dinucleotide (NAD+) participate in these 
electron transfer reactions and can act as oxidizing (NAD+) or reducing agents (NADH). NADH can 
be further metabolized during oxidative phosphorylation, the electron transport chain across the inner 
mitochondrial membrane, to generate more ATP. Its related cofactor NAD phosphate (NADP+) is 
reduced to NADPH during the oxidative phase of the pentose phosphate pathway (PPP) in the cytosol. 
NADPH is an essential reducing agent, not only for anabolic reactions like nucleic acid synthesis, but 
also for the production and elimination of reactive oxygen species (ROS). ROS—as the name 
implies—are a heterogenic group of highly reactive molecules and a normal byproduct of metabolic 
redox reactions [1]. Among them are free radicals, which hold an unpaired valence shell electron, like 
superoxide (•O2−), nitric oxide (NO•) or the hydroxyl radical (•OH), and oxidizing molecules such as 
hydrogen peroxide (H2O2) or hypochlorus acid (HOCl). ROS are important mediators of cell signaling 
(called redox signaling) [2] and are indispensable for the immune defense in macrophages. The 
enzyme NADPH oxidase, for example, generates superoxide from molecular oxygen, which is then 
used to kill bacteria in the respiratory burst reaction within the cell [3]. Nonetheless, high levels of 
ROS contribute to cell toxicity [4], since they also damage host DNA/RNA [5], oxidize proteins [6] or 
cause lipid peroxidation [7]. Therefore, the proper balance (redox state) between ROS production and 
consumption must be maintained within the cellular compartments. Enzymes such as superoxide 
dismutase (SOD), catalases or peroxidases are capable of metabolizing accumulated ROS. Catalase, 
for example, decomposes H2O2 to H2O and O2. Glutathione uses NADPH to reduce H2O2 amounts and 
to regenerate itself. Other antioxidants, such as ascorbic acid (vitamin C) and tocopherol (vitamin E), 
are described as important radical scavengers [8]. The imbalance between the production of 
metabolically derived ROS and the organism’s deficiency to detoxify the cell and to repair the 
acquired cellular damage is called oxidative stress. This condition is related to diseases like 
atherosclerosis, diabetes, pulmonary hypertension (PH), cancer or Alzheimer’s disease [9–11]. 
Constantly increased amounts of oxidizing agents activate various signaling pathways that in turn are 
targeting the promoters of “redox sensitive” genes. One of these genes encodes the zinc finger 
transcription factor early growth response 1 (Egr-1). ROS have been shown to rapidly induce Egr-1 
mRNA and protein expression [12]. Available data focusing on Egr-1 signaling after oxidative stress is 
limited and most of it is based on in vitro experiments [12–15]. Egr-1’s involvement in these 
epidemiologically relevant diseases, however, is important to understand and to develop new 
therapeutic strategies. Here we review the current data on Egr-1 in response to oxidative stress in the 
context of pathology. 
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2. Egr-1—A Redox Sensitive Transcription Factor 
2.1. Structural Properties of Egr-1 Protein 
Two exons code for an 80–82 kDa Cys2-His2-type zinc-finger transcription factor mapping to 
chromosome 5 [16]. Egr-1 was found to be rapidly and transiently expressed in response of a heterogenic 
group of stimuli like growth factors (GFs) [17], shear stress [18], oxygen deprivation [19,20], 
(reperfusion) injury [21–23] and oxidative stress [12,24,25]. The central DNA binding domain (DBD) 
of Egr-1 consists of the three zinc-finger motives [26,27] that characteristically bind to GC-rich 
promoter sequences (GCG(G/T)GGCG), therefore named Egr binding sequence (EBS) [17]. Egr-1 
interconnects a broad variety of cascades upstream and downstream. 
2.2. Functional Motifs at the Promoter 
Besides an EBS [28], several functional response elements on the Egr-1 promoter presenting targets 
of distinct signal transduction cascades have been investigated and characterized [29]. At the 3' end of 
the promoter and next to the TATA box, five serum response elements (SRE) are located [30]. Five 
Ets-family transcription factor-binding sites are arranged adjacently to these SREs. Furthermore, two 
cyclic adenosine monophosphate (cAMP) response elements (CREs), an APETALA1 (AP1) and two 
gene-specific activator protein 1 (Sp1) binding sites have been described [31]. 
2.3. Redox Regulated Transcription Capability 
Previous in vitro studies described that redox levels influence the DNA binding capacity of Egr-1 in 
a dose-dependent manner. Cys residues within the DNA-binding domain of the protein are oxidized 
and severely diminish the DNA binding capacity of Egr-1, whereas under reducing conditions, DNA 
binding is enhanced [15]. Under non-toxic ROS levels, Egr-1’s binding ability remains preserved by 
activation of an apurinic/apyrimidinic endonuclease 1 (APE1) [15,25]. APE1 is a DNA repair enzyme 
with nuclear redox activity [32–34]. In various cell types, ROS induce nuclear translocation of  
APE1 [35,36], which in turn induces DNA binding of transcriptional regulators. APE1 restores Egr-1 
DNA binding by direct protein—to protein interactions without neosynthesis and subsequently 
enhances its transcriptional activity; most likely via posttranslational modification [25]. Evidence for a 
positive autoregulatory loop between APE1 and Egr-1 exists [25]. Egr-1 upregulates APE1 by protein 
neosynthesis and APE1 in turn preserves the DNA-binding capacity of Egr-1, therefore mutually 
maintaining their transcriptional activity under non-toxic redox conditions. However, to prevent a 
never-ending activation between APE1 [37,38] and Egr-1 [28,39], the autoregulatory loop will 
eventually shut down, since APE1 binding to its own promoter leads to a downregulation by its own 
product [37].  
2.4. MAPK Signal Transduction Cascades Aiming at the SRE 
Hydrogen peroxide at non-toxic doses was shown to upregulate Egr-1 mRNA in vitro [12]. 
Moreover, Egr-1 activation was demonstrated to be MEK/ERK and c-Jun N-terminal kinases (JNKs) 
dependent in H9c2 cells; a myogenic cell line derived from the embryonic rat ventricle [40]. P42/44 
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mitogen-activated protein (MAP) kinase (MAPK), also known as extracellular signal-regulated  
kinase (ERK) 1/2, is part of the classical MAPK pathway being described to activate the Egr-1  
promoter [41,42]. ERK1/2 has been shown to be phosphorylated and therefore directly activated 
through high levels of ROS [43], such as xanthine oxidase derived H2O2 [41], though the underlying 
mechanism still remains to be elucidated. Raf, mitogen-activated protein kinase kinase kinase 
(MAPKKK), activates mitogen-activated protein kinase kinase (MAPKK = MEK) 1/2, which in turn 
phosphorylates the dual acceptor motif ERK1/2 (Thr-Glu-Tyr). Activated ERK translocates into the 
nucleus and promotes binding of Ets-family transcription factor Elk-1 to the DNA. In close proximity 
to Elk-1, the SREs binding sites are located, indicating mutual activation. Serum response factor (SRF) 
is a MADS (Mcm1 and Arg80 in yeast, Agamous and Deficiens in plants, SRF in animals) -box 
transcription factor targeting SRE binding sites, which contain the characteristic sequence 
CC(A/T)6GG also known as CArG-box [44]. SRF has been shown to be involved in the transcriptional 
regulation of various GF-inducible genes [45,46], among them Egr-1 [47]. SRF is classically dependent 
on binding of the ternary complex factors (TCFs) Elk-1, Sap1 and Sap2, to activate transcription [45]. 
Elk-1 and SRF form a ternary complex [48] and together activate transcription [49,50] combining the 
MEK/ERK pathway with SRF associated gene regulation. There are two other MAPKs, associated 
with mechanical stress, that have been found to interact with Egr-1 [51]. These are JNKs, referred to as 
stress-activated protein kinases (SAPKs) and p38 isoforms. Both of them are responsive to 
mechanical, oxidative or environmental stress [52]. The p38 kinase, however, was not found to be 
involved in H2O2 dependent upregulation of Egr-1 [42]. 
3. Egr-1 Mediated Proliferation in Hypoxia Induced Pulmonary Fibrosis and Hypertension 
Egr-1 is highly associated with growth, vascular cell proliferation [53], cell survival  
programs [18,54] and apoptosis [55]. A proliferative response to H2O2 is thought to be a protective 
mechanism against oxidant injury. Signal transduction of the H2O2-induced mitogenic signaling has 
been described to occur via the activation of MAPK and to increase the expression of Egr-1 in aortic 
smooth muscle cells [41]. Egr-1 regulates the expression of transforming growth factor beta 1  
(TGF-β1) [56] and vice versa [57]. In an in vivo model of pulmonary fibrosis, TGF-β1 promotes 
epithelial apoptosis followed by mononuclear-rich inflammation, tissue fibrosis, myofibroblast and 
myocyte hyperplasia [55]. A null mutation of Egr-1 blocked TGF-β1 induced apoptosis in vivo, 
ameliorating collagen content, alveolar remodeling and parenchymal leukocyte infiltration [55]. 
Production of ROS has been implicated in chronic hypoxia-induced pulmonary hypertension (PH) and 
pulmonary vascular remodeling. Superoxide, generated under hypoxic conditions, contributed to PH 
through the induction of Egr-1 and its downstream gene target, tissue factor (TF) [58]. Egr-1 has been 
described to further the hypoxia induced autonomous proliferation of pulmonary artery adventitial 
fibroblasts via upregulation of the cell cycle regulator cyclin D, a key mechanism in the progression of 
disease [59]. Chronic hypoxia decreased lung SOD activity and SOD overexpression attenuated 
chronic hypoxic PH and vascular remodeling. Endothelial cell (EC) derived SOD (EC-SOD) 
overexpression also prevented the early hypoxia-dependent upregulation of Egr-1 and the procoagulant 
protein TF [58]. 
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4. Apoptosis and Tumorigenesis 
Apoptosis induced by H2O2 is thought to be a direct consequence of oxidant injury. Cellular 
Abelson murine leukemia viral oncogene homolog (c-Abl) is a tyrosine kinase that can act as a 
regulator of cell growth and apoptosis in response to oxidative stress. Significantly, H2O2-induced  
Egr-1 expression in vitro seems also to be induced by c-Abl kinase activity. Furthermore, c-Abl aims 
at the three distal SREs on the Egr-1 promoter via the MEK/ERK signaling. In addition, c-Abl-induced 
apoptosis is partially mitigated by Egr-1 activity, as cells, devoid of Egr-1 expression, undergo reduced 
rates of c-Abl-induced apoptosis [60]. 
When a transcription factor is participating in cell cycle control as a physiologic response to 
hypoxia or injury [61,62], an association with tumor growth is likely to be suspected. A number of 
tumor supressor genes are regulated directly by Egr-1, among them p53 [56], and the already 
mentioned relation betweeen GFs and Egr-1 has also been described for tumor dependent  
angiogenesis [63]. Cells expressing the breakpoint cluster region-abelson (bcr-Abl) oncogene 
demonstrate increased levels of intracellular ROS [64] and signaling initiated by the bcr-Abl kinase 
causes chronic myelogenous leukemia (CML). A recent publication reported that transcriptional 
upregulation of Fyn, a ROS sensitive src-family member, was strongly dependent on Egr-1 in an  
in vitro model [65], indicating participation of Egr-1 in the pathogenesis of CML. 
In a majority of human prostate carcinoma specimens Egr-1 protein expression control was lost, 
suggesting that high levels of Egr-1 plays a central role in the initiation of human prostate cancers [66]. 
Indeed it was evidenced that Egr-1 deficient mice demonstrated impaired prostate tumor growth [67]. 
Alterations in the androgen receptor signaling were found to be a major cause of the disease and it has 
been shown that Egr-1 promotes the translocation of the androgen receptor into the nucleus [68].  
Anti-hormonal therapy of prostate cancer becomes limited in the state of androgen-independent 
disease [69] and Egr-1 seems also capable to govern prostate cancer progression under androgen 
resistance [70,71]. Therefore, Egr-1 might be a new and interesting target of anti tumor therapy 
especially when anti-hormonal drugs are no longer effective. 
5. Involvement of Egr-1 in Viral Pathogenesis 
Several viral infections lead to the activation of Egr-1 [72–74]. Infections with the Herpesviridae 
family are not only characterized by a high prevalence in the human population, such as herpes 
simplex virus 1 and 2 (HHV1/2) [75], but also have specifically been described to promote tumors 
such as the Eppstein- Barr Virus (HHV4) or the Kaposi’s sarcoma-associated herpesvirus (KSHV) also 
known as HHV8. High stress levels can trigger and reactivate viral infections that have been latent for 
a long time or even can promote virus-associated malignancies on the long term [76,77]. Egr-1 has 
also been shown to critically participate in the KSHV reactivation process directly by mediating 
transcription of the gene encoding for replication and transcription activator (RTA) [78], a viral 
component known to control the switch from latent to lytic infection [79,80]. This seems also to be 
true for the reactivation of EBV, where Egr-1 has also been shown to positively regulate RTA via a 
positive feedback mechanism [81].  
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6. Signaling Involved in the Pathogenesis of Atherosclerosis 
6.1. NADPH-Oxidase, Hemin and Egr-1 
As mentioned above, NADPH-oxidase is a ROS generating enzyme. Many different stimuli 
including angiotensin II, glucose, and oxidized LDL activate NADPH-oxidases in the vascular  
wall [82]. Furthermore, NADPH-oxidase was found in coronary specimens and a relationship between 
plaque formation and NADPH-oxidase expression could be detected [83]. Extracorpuscular heme 
(ferroprotoporphyrin IX) released from hemoglobin is a potent proinflammatory ROS inducer. Heme 
catalyzes the oxidation of LDL, thus promoting foam cell formation and vascular smooth muscle  
cell (vSMC) proliferation. Hemin, oxidized heme, has been found to mediate redox-sensitive  
gene expression and to contribute to atherosclerotic plaque progression. Via MEK/ERK, hemin 
upregulated Egr-1 in vSMCs. This was directly dependent on NADPH-oxidase activity. The novel  
NADPH-oxidase inhibitors apocynin and diphenyleneiodonium chloride were also tested and could 
block hemin induced Egr-1 expression [84].  
6.2. PKC and Egr-1 
The role of Egr-1 for the pathogenesis of atherosclerosis is quite well described [85]. The protein 
kinase C (PKC) isoforms have been shown to lie upstream of Egr-1 [86]. In human aortic smooth 
muscle cells, PKCβII and PKCФ activation and MEK/ERK mediated Egr-1 expression were essential 
for low dense lipoprotein (LDL)-induced cell proliferation [87], furthering the progression of the 
disease. It is well established, that H2O2 also leads to PKC activation [88] and in vitro, the 
autoregulatory loop between APE1 and Egr-1 was shown to be PKC dependent [25]. In an in vivo 
study, atherosclerosis was markedly impaired in mice deficient for both PKCß and ApoE when 
compared to ApoE null mice [89]. Finally, recent reports have shown that gastrin effects on Egr-1 
expression were dependent on activation of PKC family kinases, but do not require Ras (as involved in 
GF mediated MEK/ERK activation), phosphoinositol-3-kinase (PI3K) or intracellular calcium signals 
and are therefore arguing for a PKC/Raf/MEK/ERK/Egr-1 pathway [90].  
6.3. Egr-1 and Accelerated Atherosclerosis in Diabetic Disease 
It has been shown that insulin stimulates Egr-1 protein expression in endothelial cells (ECs) [91] 
and vSMCs [92] via the MEK/ERK pathway. Moreover, oxidative stress combined with insulin as 
initial stimulus further enhanced Egr-1 activation. Insulin resistance is characterized by compensatory 
hyperinsulinemia, with a functional MEK/ERK signaling but with selective impairment of PI3K [93]. 
Glucose can also induce Egr-1 expression, but PKC dependent in EC [91]. Egr-1 influences on the 
insulin gene itself could be mediated via pancreas duodenum homeobox-1 (PDX-1) [94,95], important 
for glucose homeostasis. Egr-1 signaling, PI3K or PKC might be interesting targets for drug therapy in 
atherosclerosis and diabetic disease in the future. 
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7. Conclusion—Daily Antioxidants as Dietary Supplements for the Prevention of Disease? 
Oxidizing agents such as ROS or free radicals can be initiators and mediators of disease. When 
natural detoxifying enzymes fail, oxidative stress occurs and may cause aging, atherosclerosis or 
tumors. Egr-1 is rapidly induced after exposure to oxidants and interacts with various signaling 
partners mostly in the direction of disease progression (Figure 1). 
Since Harman postulated the free radical theory of aging (FRTA) in 1956 [96], extensive research 
has been conducted to discover the key to a longer lifespan. Prevention of the formation of oxide 
radicals became an important target of the pharmaceutical industry and today a large group of  
over-the-counter drugs flood the drug market. But can the largely propagated daily supply of 
antioxidants, like vitamin C, E or selenium, in form of pills in fact reduce the incidence or outcome of 
a disease? In recent meta-analyses, the authors analyzed clinical trials investigating the oral supply of 
vitamins in tablet form on quality of life, mortality or the incidence of cardiovascular diseases and 
colon cancer. Unfortunately, they came to the conclusion that these high doses of antioxidants had no 
proven positive effect or even led to an increased mortality [97–100]. By scavenging ROS, fine-tuned 
feed back mechanisms such as the APE1/Egr-1 relation may become deranged. In turn, reducing  
ROS levels might also increase Egr-1 binding activity and even promote tumor progression or 
atherosclerosis. Therefore, the approach of disease prevention by scavenging radicals with high-dose 
supplements is neither reasonable nor safe. Probably we underestimate the complexity of fine 
regulated cellular signals in oxygen metabolism and in diseases. NADPH-oxidase inhibitors are 
currently in the very early stages of development and serious side effects regarding immune 
competence might be expected. The best guideline for a longer lifespan and the prevention of disease 
is a healthy lifestyle. This involves a balanced diet with high intake of fiber and natural antioxidants 
found in fruit and vegetables as well as daily physical activity and the cessation of smoking. Further 
studies at the molecular level are necessary to dissect the pathophysiological mechanisms behind  
ROS-induced signaling. Not until then, will we be able to design a distinct and individually matched 
therapy that will help to improve the outcome of diseases induced by oxidative stress. 
Figure 1. Overview of signaling partners involved in oxidative stress mediated Egr-1 
signaling. Oxidative stress leads to Egr-1 activation (↑) and promotes atherosclerosis, 
diabetes, apoptosis and pulmonary hypertension. The MEK/ERK pathway is the main 
signal transduction cascade involved. Depending on the targeted cell type and in vitro or  
in vivo data, different elements are involved.  
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